Novartis to Buy Myricx Bio for Up to $1.5 Billion
Novartis has entered into an agreement to acquire UK-based biotechnology firm Myricx Bio in a deal valued at up to $1.5 billion.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Novartis is moving to acquire Myricx Bio to integrate the company’s assets into its existing pipeline. The transaction involves an initial upfront payment of $1.1 billion, with the total valuation reaching $1.5 billion based on potential milestones.
Coverage from the Financial Times, Bloomberg, the Wall Street Journal, Fierce Biotech, and Business Wire emphasizes the acquisition’s role in expanding Novartis’s antibody-drug conjugate (ADC) capabilities. Reporting highlights the involvement of Sofinnova Partners in the announcement.
Future developments will depend on the formal closing of the transaction and the integration of Myricx Bio’s research into the Novartis cancer-drug portfolio. Further updates regarding the specific timeline for the finalization of the deal are pending.
Synthesized by headlinez.news from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 1h ago.
Quick answers
What is the total value of the acquisition?
The deal is valued at up to $1.5 billion.
How much is the upfront payment?
Novartis is set to pay $1.1 billion upfront.
What is the primary focus of the acquisition?
The purchase is intended to expand the Novartis antibody-drug conjugate (ADC) pipeline.
Coverage (7)
- Four major biotech updates to catch up on STAT · 9h ago
- Novartis acquires U.K. cancer biotech Myricx Bio for $1.5 billion qz.com · 9h ago
- Sofinnova Partners Announces Myricx Bio Agrees to Be Acquired by Novartis Business Wire · 9h ago
- Novartis to buy UK biotech Myricx Bio in $1.5bn deal Financial Times · 9h ago
- Novartis to pay $1.1B upfront for Myricx to expand ADC pipeline Fierce Biotech · 9h ago
- Novartis to Buy Cancer-Drug Firm Myricx for Up to $1.5 Billion Bloomberg.com · 9h ago
- Novartis to Buy Myricx Bio for Up to $1.5 Billion WSJ · 9h ago
Topics
Related trends
Scribe Therapeutics files for IPO in test of public appetite for earlier-stage biotechs
Biotech IPO test: Scribe Therapeutics targets $75M valuation amid early-stage investor scrutiny
AI company Anthropic announces it will begin developing drugs of its own
Anthropic shifts from AI to drug discovery, targeting diseases Big Pharma ignores
FDA’s top gene therapy regulator is leaving his role
Leadership transitions at the FDA coincide with a significant regulatory rejection for Unicycive Therapeutics.
French biotech stock soars 34% after new data on experimental medicine
Shares of French biotech firm Abivax have surged following the release of new clinical safety data regarding its experimental ulcerative colitis medication.
Talawar Therapeutics and JATT II Acquisition Corp. Announce Definitive Business Combination Agreement to Create Publicly Listed Biotechnology Company Developing Potentially Best-in-Class Bispecifics for I&I Diseases
Talawar Therapeutics is set to become a publicly traded company following a definitive business combination agreement with JATT II Acquisition Corp.
Ipsen to Buy Kartos Therapeutics for Up to $1.75 Billion
Ipsen’s $1.75B bid for Kartos Therapeutics reshapes blood cancer drug development—with a twist on the deal’s structure